HeartSciences Inc. (HSCS) Form SCHEDULE 13D/A — Oct 23, 2026
HeartSciences CEO, President and Chairman Andrew Simpson filed a Schedule 13D/A reporting beneficial ownership of 403,739 shares of common stock, or 7.5% of the class, held for investment purposes with no active plans or proposals for the company. The stake comprises 4,382 common shares, 5,523 shares issuable on conversion of Series C preferred, 323,833 stock options, and 70,000 restricted shares. All options fully vested on October 5, 2026, upon the FDA's 510(k) clearance (K260005) of the company's MyoVista wavECG device, and his 70,000 restricted shares vest upon closing of the pending merger with Fortitude Mining Holdings.
Key figures
- Shares Outstanding
- 4969283
- Options
- 323833
- Percent Owned
- 7.5%
- Notes Principal
- $1.5 million 12% secured subordinated convertible promissory notes
- Fda Clearance Date
- 2026-10-05
- Restricted Shares
- 70000
- Series CPreferred Shares
- 342841
- Beneficially Owned Shares
- 403739
- Excluded Unvested Restricted Shares
- 425000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.